Oncology

PB (MM) 4101

PB (MM) 4101 is a biobetter of a complex biologic successfully produced at small, medium and large scale. Paras Biopharma has developed production process and scaleup technology for this proposed biobetter. Thorough analytical characterization has been done. The Biobetter presents significant market opportunities for un-met medical needs and patient convenience of product application.

PB (CT) 4020

PB (CT) 4020 is an scFv in preclinical development. More details will follow.




Osteoporosis Rheumatoid Arthritis Diabetes (Metabolic Disorder) AMD (Biosimilar Lucentis Ranibizumab) Oncology Market Insights